Express Pharma

Pharmexcil felicitates leading pharma players

0 101

The Pharmaceuticals Export Promotion Council of India (Pharmexcil) recently organised the India-Asia-Pacific Pharma Business Meet and the Annual General Body meeting of the Council wherein Pharmexcil awarded several pharma companies for their significant contributions to the sector.

The event witnessed the presence of various successful companies who came together to share and recognise their achievements of securing patents in the pharma sector in 2011-12. Held in Hyderabad, the event was conferred by Raja Shekhar, IAS, Joint Secretary Department of Pharmaceuticals, Ministry of Chemicals & Fertilisers and RP Thakur, DGDC, AP. Some of the winners are as follows:

Venus Remedies who received four patents in this fiscal year with two patents each for Sulbactomax and Vancoplus won the Patent Award in Silver category for the year 2011-12. Hyderabad-based Bharat Biotech also received the Silver Patent Award for the year 2011-12 in recognition of commendable contribution in biotech products and research. The‘Outstanding Export Performance Award’ for the year 2011-2012 went to Calyx Chemicals and Pharmaceuticals, recognising the company’s performance as a supplier of excellent quality products and reliability.The winners were buoyant after receiving the awards.

Dheeraj Aggarwal, CFO, Venus Remedies after receiving the award at the ceremony said, “Getting such a prestigious award for the second year in a row for our commendable contributions towards research and development, demonstrated by patent grants in 2011-12, is indeed a matter of pride and great honour.”

Dr Krishna Ella, Chairman and MD, Bharat Biotech stated, “We thank Phamexcil for recognising innovation at Bharat Biotech and the credit goes to the Bharat Biotech Team, who have worked relentlessly to make this happen.”

The Pharmexcil jury recommended and selected winners based on the guidelines framed for selection.

EP News Bureau

- Advertisement -

Leave A Reply

Your email address will not be published.